January 29, 2019 HOOFDDORP, The Netherlands–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, is launching DUROLANE, its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. It’s estimated that up to …